Amer Zeidan, MBBS, MD

Amer Zeidan, MBBS, MD

Professor of Medicine (Hematology) — Yale School of Medicine

Dr. Zeidan is Chief of the Division of Hematologic Malignancies and Director of Early Therapeutics Research and the Leukemia and Myeloid Malignancies Program at Yale Cancer Center. He specializes in myeloid malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia, with research focused on novel targeted and immunotherapy-based treatments. He earned his MBBS from the University of Jordan, completed residency at Rochester General Hospital, and hematology/oncology fellowship at Johns Hopkins Hospital, where he also earned an MHS in Clinical Investigation. He has authored more than 360 peer-reviewed publications and received multiple national research awards.

Areas of Focus: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancies, Early-Phase Clinical Trials, Immunotherapy

Latest Content

Medical professionals discussing treatment options for myelodysplastic syndromes in a clinical setting.

Videos & Podcasts

08/18/2026

Navigating Frontline Treatment and Disease Progression in Myelodysplastic Syndromes

Group photo of five medical professionals discussing personalized therapy decisions in myelodysplastic syndromes.

Evolving Approaches: Low-Risk MDS

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Panel of five medical experts discussing managing imetelstat toxicities in lower-risk MDS during OncUpdates episode 3.

Evolving Approaches: Low-Risk MDS

08/04/2026

Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS

Panel of five medical experts discussing treatment sequencing in lower-risk MDS at OncUpdates.

Evolving Approaches: Low-Risk MDS

08/01/2026

Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS

Group photo of five medical professionals discussing next-generation sequencing and IPSS-M in lower-risk MDS for OncUpdates episode 1.

Evolving Approaches: Low-Risk MDS

07/29/2026

Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS

Evolving approaches in low-risk myelodysplastic syndromes with expert doctors Dr. Yasmin Abaza, Dr. Thomas LeBlanc, Dr. Hetty Carraway, Dr. Rahul Gosain, and Dr. Amer Zeidan.

Evolving Approaches: Low-Risk MDS

07/28/2026

The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes

Panel of four medical experts discussing managing side effects of Luspatercept in a professional setting.

Luspatercept in Low-Risk MDS

06/25/2026

Managing Side Effects of Luspatercept

Image featuring Dr. Jamile M. Shammo, Dr. Tiffany Tanaka, Dr. Rohit Gosain, Dr. Amer Zeidan, and Dr. Christopher Benton discussing low-risk MDS and clinical trial data.

Luspatercept in Low-Risk MDS

06/24/2026

Luspatercept: Clinical Trial Data and Lessons for Low-Risk MDS